Neoadjuvant treatment with olaparib prior to surgical resection and adjuvant chemotherapy was well tolerated and led to a 100% optimal resection rate in patients with newly diagnosed, BRCA-mutant ovarian, primary peritoneal, or fallopian tube cancer.
This is an edited version of an article by Carolyn Seymour published in OncLive Mar. 28, 2023
A triplet regimen comprised of COM701, BMS-986207, and nivolumab (Opdivo) was found to have encouraging antitumor activity and favorable tolerability in patients with heavily pretreated, platinum-resistant ovarian cancer.
This is an edited version of an article by Ryan Scott published in OncLive Jan. 12, 2023
Mirvetuximab soravtansine has been approved by the FDA for the treatment of recurrent platinum-resistant high-grade serous ovarian cancer that highly expresses the folate receptor alpha. Clinical testing of this new therapy has been co-led by Dr Ursula Matulonis, MD.
This is an edited version of a news release published by Dana Farber Cancer Institute on Nov. 14, 2022
On November 14, 2022, the FDA granted accelerated approval to mirvetuximab soravtansine for the treatment of adult patients with folate receptor α (Frα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1 to 3 prior systemic treatment regimens.
This is an edited version of an article written by Caroline Seymour and published in OncLive Nov. 15, 2022
Pembrolizumab (Keytruda) monotherapy induced durable clinical outcomes in heavily pretreated patients with clear cell gynecologic cancer (CCGC), according to findings from the phase 2 PEACOCC trial (NCT03425565).
This is an edited version of an article written by Jason Ryan and published in OncLive Oct. 17, 2022
Frontline niraparib (Zejula) maintenance sustained a progression-free survival (PFS) benefit in patients with advanced ovarian cancer, according to updated data from the phase 3 PRIMA trial presented at the 2022 ESMO Congress.
This is an edited version of an article written by Ryan Scott and published in OncLive Oct. 12, 2022
A global study into mucinous ovarian cancer could help oncologists recommend the best treatment for women who are diagnosed early with the condition.
This is an edited version of an article reviewed by Emilie Henderson, B.Sc., and published on News-Medical.Net Oct. 12, 2022
Two new discoveries led by Cedars-Sinai Cancer investigators help improve the understanding of what drives the development of ovarian cancer and why some women’s tumors do not respond to therapy.
This is an edited version of an article reviewed Emilie Henderson, B.Sc., and published on News-Medical.Net Oct. 11, 2022
Maintenance treatment with niraparib (Zejula) produced a sustained and durable progression-free survival (PFS) benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups, according to updated data from the phase 3 PRIMA trial….
This is an edited version of an article written by Kristi Rosa and published in OncLive Sept. 15, 2022
Rucaparib (Rubraca) maintenance therapy improved progression-free survival (PFS) vs placebo in patients with newly diagnosed ovarian cancer, according to disease risk subgroup analyses from the phase 3 ATHENA–MONO study….
This is an edited version of an article written by Hayley Virgil and published in OncLive Sept. 11, 2022
If you are having issues printing the applications or have questions on how to fill them out and submit them, complete this form and someone will get back to you soon.
Fill out this form to receive an email reminder when the retreat applications are available.
